Technology from Pall Life Sciences will be used New York Blood Centre’s (NYBC) new filtration system, which aims to improve efficiency when removing white blood cells from donated blood.

The Pall technology, Leukotrap RC System with RC2D Filter, incorporates a process (leukoreduction)that provides a blood product with fewer white blood cells. NYBC determined that Pall’s new in-line filtration process will help the centre effectively deliver leukoreduced red blood cells to meet increased hospital demand.

visit www.pall.com

Leave a Reply